Arrowhead Subsidiary, Insert Therapeutics, to Present at NSTI Nanotech 07 Conference.PASADENA, Calif. -- Arrowhead Research Corporation (Nasdaq:ARWR) announced today that Dr. Thomas Schluep, Chief Scientific Officer of Insert Therapeutics, a majority owned subsidiary of Arrowhead, will present at the Nanotech for Investors Summit at the Nano Science and Technology Institute 2007 Conference on May 21, 2007 in Santa Clara, California Santa Clara, California (IPA: /ˌsæntəˈklærə/) , founded in 1777 and incorporated in 1852, is a city in Santa Clara County, in the U.S. state of California. . Dr. Schluep's presentation, entitled "Insert Therapeutics Product Development Update," will highlight Insert's technical and clinical progress in using its proprietary polymeric transport system, Cyclosert(TM), to design, develop and commercialize nanoparticle-enhanced small-molecule therapeutics. Insert's lead drug candidate, a combination of its linear, cyclodextrin-based polymer and the anti-cancer compound camptothecin, entered the clinic in 2006. Dr. Schluep is responsible for Insert's drug discovery and development programs. Prior to joining Insert in 2004, Dr. Schluep was in charge of the non-viral gene therapy program at Canji, Inc., a wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. of Schering-Plough. While at Canji, he held multiple positions of increasing responsibility in the development, manufacture, and analytical testing of non-viral and adenoviral gene therapy vectors. A constant interest of Dr. Schluep has been to understand the role nanotechnology can play in enhancing the efficacy and therapeutic index of a wide variety of therapeutics. He holds a Sc.D. in Process Engineering and an MS in Biotechnology, both from the Swiss Federal Institute of Technology The Swiss Federal Institute of Technology may refer to one of two institutes of higher education in Switzerland:
About Arrowhead Research Corporation Arrowhead Research Corporation (www.arrowheadresearch.com) is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials Semiconductor materials are insulators at absolute zero temperature that conduct electricity in a limited way at room temperature (see also Semiconductor). The defining property of a semiconductor material is that it can be doped with impurities that alter its electronic properties . About Insert Therapeutics Insert Therapeutics, Inc. (www.insertt.com), a majority-owned subsidiary majority-owned subsidiary A firm in which more than 50% of outstanding voting stock is owned by the parent company. of Arrowhead Research Corporation (NASDAQ:ARWR), is using its proprietary, nano-engineered, polymeric delivery system, Cyclosert(TM), to design, develop and commercialize drug-delivery-enhanced small-molecule therapeutics and nucleic acids Nucleic acids The cellular molecules DNA and RNA that act as coded instructions for the production of proteins and are copied for transmission of inherited traits. . Cyclosert uses cyclodextrins as building blocks to create an entirely new class of biocompatible materials - linear cyclodextrin-containing polymers that are non-toxic and non-immunogenic at therapeutic doses. Insert's affiliate company, Calando ca·lan·do adv. & adj. Music With a gradual decrease in volume and often tempo. Used chiefly as a direction. [Italian, present participle of calare, to slacken Pharmaceuticals, is using a related system for the systemic delivery of siRNA. The companies are pursuing this goal through internal research and development, and also through collaborations and partnerships with pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. . Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q Form 10-Q See 10-Q. and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statements on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion